Thank you for submitting your manuscript on Nek2A/Kif18A ubiquitination determinants to The EMBO Journal. Three experts have now reviewed it and provided detailed comments, which you will find copied below. Unfortunately, their assessments offer insufficient support for publication in The EMBO Journal. As you will see, the referees appreciate that the manuscript reports several findings of potential interest, including the identification of Kif18A as a new APC/C substrate and the implication of additional early destruction determinants in Nek2A. However, the reports at the same time show the reviewers remaining unconvinced that your present set of data and experiments is sufficiently complete, and sufficiently conclusive, to justify the current interpretations and key conclusions. Among the various concerns raised in this regard, major issues with experimental conclusiveness concern the Nek2A leucine zipper data or the APC8 requirement data; while completeness and thoroughness of the analysis is for example questioned with regards to considering the respective contributions of all the classical and non-classical degrons and interaction motifs in Nek2A and Kif18A. I will not go through all the individual points of criticism in this letter, but I am afraid that the extent and importance of these shared critical opinions leave me little choice but to conclude that the study is not a good candidate for publication in The EMBO Journal at this point. As you hopefully understand, we can in light of our high number of submissions only invite revision and proceed further in those few cases where manuscripts are met with elevated enthusiasm from at least a majority of referees already upon initial review, and where there seems to be a fair chance of substantiation to the reviewers' satisfaction during a limited period of revision. In any case, thank you once more for the opportunity to consider this work. I am sorry we cannot be more positive on this occasion, but nevertheless hope that you will find our referees' detailed comments 1. I am concerned that Venus Nek2A constructs might have different effects on cell cycle progression as the timing to initiate anaphase after NEBD varies ( Figure 3 and Figure 5 ), depending on the constructs and experiment (between 15 min and 50 min). The authors should include an explanation in the text. It is possible that the mutations could cause an indirect effect on the timing of Nek2A degradation in this assay.
2. Figure 4A . Please explain why the Venus-Nek2A 265-445 construct produces such a GFP rich band. Is this fusion protein unstable in cells and cleaved? In contrast, Figure S3 suggests that it is stable. Is it possible that the authors measured degradation of GFP (Venus), rather than the fusion protein in Figure S3 ? If the authors' hypothesis is correct, 265-445 could degrade reasonably well in prometaphase because it has both the LZ and MR motif.
3. Figure 4B . The pull down assay using anti-APC4 antibody suggests that LZ mutations reduce the interaction between Nek2A and APC/C. However, the mutations could inhibit formation of the Nek2A dimer as suggested in Figure 4D . If so, the reduced recovery of Nek2A may be due to defects on its dimer formation, rather than direct interaction between Nek2A and the APC/C. I would rather suggest to re-do the experiment in a reciprocal way; pull down using anti-Nek2A antibody (FLAG) and measure the amount of APC/C co-purified.
4. Figure 6B -D. Depletion of APC8 reduced the recovery of Nek2A as well as that of several APC/ C subunits, but recoveries of several APC/C subunits are not shown in this Figure. Therefore, it is possible that Nek2A interacts with other APC/C subunit such as APC1, APC5, APC6 or APC7. It is too preliminary to conclude that APC8 has a critical role in Nek2A binding.
5. Figure 6E . If the authors propose that the strength of affinity binding to the APC/C determines the timing of substrate destruction, more direct evidence should be provided, for example, checking the affinity of cyclin B, Nek2A and Kif18A and Aurora A to the APC/C and the timing of their destruction by live cell imaging. The ubiquitination assays of cyclin B and Nek2A do not support their model as cyclin B was more efficiently ubiquitinated than Nek2A ( Figure 6A ).
6. The authors do not mention the KEN-box of Nek2A at all. I would like to know the contribution of the KEN-box in Nek2A degradation during prometaphase. In addition, the KEN-box might be more important than the MR motif in Nek2A degradation in anaphase. Have the authors investigated Venus Nek2A KEN, Nek2A KEN MR or Nek2A 333-445 KEN in the live cell degradation assay?
Minor points:
1. Figure 2B , why is tubulin increased if Cdh1 is depleted? 2. Figure 2B and C, the same control (tubulin or vinculin) should be used to compare the effect of Cdh1 or Cdc20 depletion. The panels should be arranged in the same order in both experiments 3. Figure 2C . Aurora A destruction is inhibited by Cdc20 depletion, although the authors mention that Aurora A is a well-characterized Cdh1 substrate. Please explain why.
Referee #2 (Remarks to the Author):
Sedgwick et al identify a novel APC/C substrate Kif18A. Its degradation is dependent on its Cterminal LR motif (similar to the IR tail of coactivators and Apc10 and MR tail of Nek2A). However Kif18A is degraded at anaphase and the MR of Nek2A is not sufficient to target Kif18A for degradation during an active checkpoint. The authors investigate timing of Nek2A degradation and show that a Leu-zipper (residues 310-34) is required for high affinity binding and for Nek2A degradation in prometaphase.
There are some interesting findings in this manuscript, but in places the data are not completely convincing, experiments are incomplete and some of their data could be interpreted differently.
Comments:
1. Fig. 1A , page 6. The authors do not detect Nek2A bound to APC/C in the presence of nocodazole. This is a bit surprising since Nek2A is ubiquitinated by the APC/C during an active SAC. Furthermore later in the manuscript on page 10 and shown in Fig. 4A the authors do detect Nek2A-APC/C interactions in the presence of nocodazole.
2. The presence of D box and KEN box degrons in Kif18A was not discussed. Do these determine timing of Kif18A degradation? What determines the dependence of Kif18A degradation on satisfying the SAC? The authors discuss that the LR motif is recognised at anaphase when the APC/C becomes fully active. Can the authors suggest a mechanistic explanation? Can the authors explain why Kif18A degradation is dependent on both Cdc20 and the LR motif? 3. Page 9. The selection of Nek2A constructs for testing timing of degradation and APC/C binding wasn't explained.
4. (Page 9) Constructs 333-445 contains KEN and D box whereas 370-445 would have a KEN box. Therefore isn't it expected that these constructs lacking the MR tail would be degraded at anaphase? Fig. 3 shows a sharp degradation of 333-445 at anaphase whereas a slower decline for 370-445 perhaps reflecting the D box present in 333-445. 5. Page 10 (Fig. 4) authors suggest that the region 265-333 of Nek2A contributes to high affinity binding to APC/C and 'potentially explains why Nek2A 333-445 is not degraded until anaphase.' The authors should show that the leucine zipper and MR tail mimic the degradation pattern of full length Nek2A. It isn't clear why Nek2A 265-445 is not a substrate of the APC/C whereas 333-445 and 370-445 are.
6. The authors propose that Nek2A binds to apo-APC/C and its degradation is controlled by Cdc20. What distinguishes Nek2A from binding to APC/C-Cdc20 at prometaphase from securin and cyclin B which isn't degraded at prometaphase? 7. Fig.5 shows that the leu zipper is required to confer Nek2A degradation during an active SAC. Although the authors interpret their data to indicate the Leu zipper is required to mediate high affinity Nek2A-APC/C binding, they don't discuss whether this is due to direct binding to the APC/C (in the context of Nek2A) or the possibility that the Leu zipper plays a structural role to position the D box, KEN box and MR motifs in the optimal orientation for APC/C binding.
8. The authors should explain why when describing the data in Fig. 6A (page 12) they indicate that the ubiquitination of cyclin B, Nek2A and Nek2A 333-445 are similarly sensitive to the SAC, when it would have been expected that only Nek2A would be a substrate of SAC-inhibited APC/C. In fact there appears little difference between rates of Nek2A ubiquitination between SAC-inhibited and uninhibited APC/C -and in both conditions the degree of Nek2A ubiquitination is very low despite the high amounts of unmodified Nek2A (Fig. 6A). 9. In the RNAi experiment Fig. 6B , depletion of Apc8 (and IP on Apc4) also leads to loss of Apc10 and Apc11. This indicates that depletion of Apc8 leads to almost complete disassembly of the APC/C (not just loss of Apc8, Apc6 and Apc3 as the authors mention). From this experiment it is not possible to conclude that Nek2A binds to Apc8.
10. In Fig. 6F . In the presence of MG132 why didn't the authors test Nek2A binding to the APC/C-MCC (IP on BubR1)? 11. What is the evidence that Cdc20 is required for Nek2A degradation at prometaphase -as mentioned in the Abstract and last line of the Introduction?
12. Indicate prometaphase and metaphase on plots in Fig. 3. 13. Other points. The manuscript contains numerous typographical and grammatical errors and references are incomplete.
Referee #3 (Remarks to the Author):
The anaphase-promoting complex or cyclosome (APC/C) in collaboration with its mitotic activator Cdc20 mediates the ubiquitination of many mitotic regulators, resulting in their orderly destruction that drives mitotic progression. APC/C-Cdc20 is the target of the spindle checkpoint, which limits APC/C activity until all sister kinetochores achieve bi-orientation. Certain APC/C substrates such as Nek2A escape checkpoint inhibition and are degraded prior to the metaphase-anaphase transition. The mechanism by which Nek2A escapes checkpoint inhibition is incompletely understood, but has been shown to require the binding of its C-terminal MR motif to APC/C. In the current study, Sedgwick et al. further investigated the mechanism by which Nek2A evaded the checkpoint. They began their study by identifying Kif18A as a novel APC/C-Cdc20 substrate and show that it too required the C-terminal LR motif for ubiquitination. Unlike Nek2A, Kif18A ubiquitination and degradation are regulated by the spindle checkpoint, however. This result promoted the authors to search for additional determinants in Nek2A that mediate its degradation when the checkpoint is on. These efforts led to the evidence that implicated a requirement for the leucine-zipper motif of Nek2A in this process. Overall, their results provide additional insights into how APC/C recognizes substrates and how the checkpoint regulates substrate recognition by APC/C. These findings are significant, and are in principle appropriate for publication in EMBO J. The authors need to address my following concerns prior to publication.
Major points:
(1) The authors conclude the APC/C-binding activity of the leucine-zipper is dependent of its ability to mediate dimerization. This conclusion is not well supported by their data. If the LL-AA mutant of Nek2A only weakens APC/C binding slightly (as the authors argue), how does the coiled coil motif contribute to APC/C-dependent ubiquitination? It remains formally possible that both MR motifs in the wild-type Nek2A homodimer cooperatively engage APC/C. Mutations of the leucine-zipper disrupt the dimerization of Nek2A, and as a consequence, weaken the bipartite interaction between MR and APC/C. This is consistent with the fact that the isolated leucine-zipper domain of Nek2A does not bind to APC/C. Obviously tethering the MR motif to the dimeric Kif18A was not sufficient to confer prometaphase degradation, indicating that dimerization of MR motif per se is not sufficient. The authors should nonetheless test whether tethering Nek2A MR motif to a small leucine-zipper domain found in transcription factors would be sufficient to create an APC/C substrate that evades the spindle checkpoint.
(2) The paper contains two novel discoveries: the identification of Kif18A as an APC/C-Cdc20 substrate and the identification of the leucine-zipper motif as an additional determinant for prometaphase degradation of Nek2A. The connection between these two discoveries is obvious, but not as strong as it can be. The authors should do a better job in their writing to integrate these two findings.
Appeal 04 July 2012
Thank you for your comments on our manuscript concerning the analysis of Kif18A and Nek2A.
Overall the comments from all three reviewers appear positive but unfortunately there are several major points that they misunderstood. This may reflect that we did not explain our experiments and conclusions well enough. Nevertheless there are relevant points raised by the reviewers but we can certainly address these within a reasonable timeframe. I have written our response to the reviewers comments below and also detailed the experiments we intend to perform to address their concerns. Given the overall positive statements and the fact that the reviewers have misunderstood several key points of the manuscript, I hope that you will reconsider your decision and provide us with the opportunity to submit a revised version.
**************************************************** Referee #1 (Remarks to the Author):
This manuscript describes how Nek2A can be destroyed even when the spindle assembly checkpoint (SAC) is active. The APC/C was purified from nocodazole-arrested and released HeLa cells and associated proteins determined by mass spectrometry. The authors identified Kif18A and Nek2A and intriguingly both proteins terminate in a similar dipeptide motif to Cdc20/Cdh1 (IR); LR in Kif18A and MR in Nek2A. Initial studies showed that Kif18A destruction during mitosis wasdependent on the LR motif and Cdc20. However, Kif18A was degraded in anaphase, unlike Nek2A which starts to degrade in prometaphase. Thus, investigation into the mechanism of Nek2A degradation during prometaphase was carried out. Theauthors showed that the MR motif in Nek2A was not sufficient to target it for degradation during an active checkpoint but the region from 265-333 might be involved. From further investigation, the conclusion that the leucine zipper of Nek2A in combination with the MR motif is essential to provide its higher affinity binding to the APC/C in prometaphase was proposed. It is an interesting model, however, the data quality and interpretation raises someconcerns. The manuscript will be improved if the following points are addressed.
Major Points:
1. I am concerned that Venus Nek2A constructs might have different effects on cell cycle progression as the timing to initiate anaphase after NEBD varies ( Figure 3 and Figure 5 ), depending on the constructs and experiment (between 15 min and 50 min). The authors should include an explanation in the text. It is possible that the mutations could cause an indirect effect on the timing of Nek2A degradation in this assay.
Our response:
The difference in timing in Figure 3 and Figure 5 do not reflect an impact of the different Nek2A constructs on mitotic progression. The time of mitotic progression in individual cells varies and we simply choose cells that nicely represented the timing of degradation. We have analyzed the impact of non-degradable Nek2A on mitosis but there is no effect at physiological expression levels. We will include statistics on NEBD-Anaphase times for the different Nek2A constructs in the revised version of the manuscript.
2. Figure 4A . Please explain why the Venus-Nek2A 265-445 construct produces such a GFP rich band. Is this fusion protein unstable in cells and cleaved? In contrast, Figure S3 suggests that it is stable. Is it possible that the authors measured degradation of GFP (Venus), rather than the fusion protein (Venus-Nek2A 265-445) in Figure S3 ? If the authors' hypothesis is correct, 265-445 could degrade reasonably well in prometaphase because it has both the LZ and MR motif.
Our response: This is a valid point and we will repeat to check if there is any sign of degradation such that free GFP is generated, which may explain why we do not see degradation of Nek2A 265-445. We will also analyze additional Nek2A constructs that contain both the LZ and MR motif to determine when they are degraded.
3. Figure 4B . The pull down assay using anti-APC4 antibody suggests that LZ mutations reduce the interaction between Nek2A and APC/C. However, the mutations could inhibit formation of the Nek2A dimer as suggested in Figure 4D . If so, the reduced recovery of Nek2A may be due to defects on its dimer formation, rather than direct interaction between Nek2A and the APC/C. I would rather suggest to re-do the experiment in a reciprocal way; pull down usinganti-Nek2A antibody (FLAG) and measure the amount of APC/C co-purified.
We were quite careful in measuring the extent of Nek2A L313A/L320A binding to the APC/C and to Nek2A WT by Licor, it is clear that the mutant is strongly defective in dimerization to Nek2A WT while there is only a slight reduction in APC/C binding. Off course we are aware of the difficulty in discriminating between a direct effect of the leucine-zipper in binding to the APC/C and its role in dimerization, which is why we invested effort into this. We will perform the suggested experiments and purify Nek2A constructs and look at their binding to the APC/C and also investigate the timing of degradation of Nek2A L313A/L320A in our live cellassay.
4. Figure 6B -D. Depletion of APC8 reduced the recovery of Nek2A as well as that of several APC/ C subunits, but recoveries of several APC/C subunits are not shown in this Figure. Therefore, it is possible that Nek2A interacts with other APC/C subunit such as APC1, APC5, APC6 or APC7. It is too preliminary to concludethat APC8 has a critical role in Nek2A binding.
Our response: This is a valid point but based on the literature it is clear that APC8 depletion (as well as APC6 depletion) splits the APC/C into 2 subcomplexes. We will include blots of several additional APC/C subunits to illustrate this point. Futhermore we are in the process of performing RNAi rescue experiments with APC8 WT and an APC8 mutant defective in Cdc20 binding in prometaphase (described in Izawa and Pines 2011) to determine if this same mutant prevents Nek2A binding and will include this analysis in the revised manuscript.
Our response:
We only propose that the affinity of Nek2A for the APC/C has to be high for it to be a substrateduring prometaphase not that there is a general correlation between affinity of a substrate and its timing of degradation. The cyclin B1 used in figure 6A is the N-terminus of cyclin B1 and not the full length protein and is a very efficient substrate used extensively in APC/C research because it is such an effective substrate. The in vitro APC/C assays are useful for determining certain aspects of APC/C biology but there is not necessarily a good correlation on how a substrate behaves in vitro and in vivo. In addition the MCC dissociates during in vitro ubiquitination reactions (see Mansfeld 2011), which results in less difference between APC/C activity in the two preparations used. We only use this assay to show that Nek2A is sensitive to the presence of the SAC and nothing more in agreement with work from Jan-Michael Peters lab(Herzog 2009).
We have analyzed the role of the KEN box in the context of full length Nek2A but this does not affect its timing of degradation and therefore we did not include it in theoriginal submission. We will include it in the revised version.
1. Figure 2B , why is tubulin increased if Cdh1 is depleted?
Our response: This is a transfer problem and we will redo to get a better blot.
2. Figure 2B and C, the same control (tubulin or vinculin) should be used to compare the effect of Cdh1 or Cdc20 depletion. The panels should be arranged in the same order in both experiments
Our response: We will do this correction.
3. Figure 2C . Aurora A destruction is inhibited by Cdc20 depletion, although the authors mention that Aurora A is a well-characterized Cdh1 substrate. Please explain why.
Our response: This is because Cdc20 depletion appears to slow mitotic exit even in the presence of a Cdk1 inhibitor, which indirectly affects Aurora A degradation because Cdk1 inhibits Cdh1.
1. Fig. 1A , page 6. The authors do not detect Nek2A bound to APC/C in the presence of nocodazole. This is a bit surprising since Nek2A is ubiquitinated by theAPC/C during an active SAC. Furthermore later in the manuscript on page 10 and shown in Fig. 4A the authors do detect Nek2A-APC/C interactions in the presence of nocodazole.
Our response: Nek2A is degraded in nocodazole and that is off course why we do not detect it in Fig 1A . In allexperiments were we detect binding of endogenous Nek2A to the APC/C MG132 is added before to stabilize Nek2A, whereas we look at exogenous Nek2A levels in fig 4A. It appears that Nek2A is being actively translated in mitosis similar to Cdc20 and that is why adding MG132 increases Nek2A levels.
2. The presence of D box and KEN box degrons in Kif18A was not discussed. Do thesedetermine timing of Kif18A degradation? What determines the dependence of Kif18A degradation on satisfying the SAC? The authors discuss that the LR motif is recognised at anaphase when the APC/C becomes fully active. Can the authors suggest a mechanistic explanation? Can the authors explain why Kif18A degradation is dependent on both Cdc20 and the LR motif?
We have analyzed the degradation of different Kif18A truncations, 453-898, 653-898, 800-898 and this shows that 453-898 is still a anaphase substrate while 653-898 and 800-898 are stable. The region from 453 to 653 does not contain any strong KEN or D-boxconsensus but we will discuss this in the revised version and include the analysis of these constructs in the revised version. We will also test if Kif18A binding to the APC/C is sensitive to Cdc20 depletion in contrast to Nek2A.
3. Page 9. The selection of Nek2A constructs for testing timing of degradation and APC/C binding wasn't explained.
We will include a discussion of this in the revised manuscript.
4. (Page 9) Constructs 333-445 contains KEN and D box whereas 370-445 would have a KEN box. Therefore isn't it expected that these constructs lacking the MR tail would be degraded at anaphase? Fig. 3 shows a sharp degradation of 333-445 at anaphase whereas a slower decline for 370-445 perhaps reflecting the D box present in 333-445.
We will include a discussion of this in the revised manuscript. We mainly focused our efforts in trying to understand how Nek2A is degraded during an active checkpoint as this is a very unusual behavior.
5. Page 10 (Fig. 4) authors suggest that the region 265-333 of Nek2A contributes to high affinity binding to APC/C and 'potentially explains why Nek2A 333-445 is not degraded until anaphase.' The authors should show that the leucine zipper and MR tail mimic the degradation pattern of full length Nek2A. It isn't clear why Nek2A 265-445 is not a substrate of the APC/C whereas 333-445 and370-445 are.
Our response: As reviewer 1 pointed out is could be due to the fact that 265-445 is cleaved from Venus inside cells, which is why we do not see degradation of 265-445. We will analyze this possibility and also analyze additional constructs containing the leuzine zipper and the MR to determine if they are substrates.
6. The authors propose that Nek2A binds to apo-APC/C and its degradation is controlled by Cdc20. What distinguishes Nek2A from binding to APC/C-Cdc20 at prometaphase from securin and cyclin B which isn't degraded at prometaphase?
Our response: It is clear from the literature that what distinguishes Nek2A from other substrates is that it does not need a co-activator for binding while securin and cyclin B do. We also show in figure 6 that depletion of Cdc20 does not affect Nek2A binding in agreement with work from the Fry lab.
7. Fig.5 shows that the leu zipper is required to confer Nek2A degradation during an active SAC.
Although the authors interpret their data to indicate the Leu zipper is required to mediate high affinity Nek2A-APC/C binding, they don'tdiscuss whether this is due to direct binding to the APC/C (in the context of Nek2A) or the possibility that the Leu zipper plays a structural role to position the D box, KEN box and MR motifs in the optimal orientation for APC/C binding.
We will expand our discussion on the role of the leuzine zipper in mediating high affinity binding to the APC/C.
8. The authors should explain why when describing the data in Fig. 6A (page 12) they indicate that the ubiquitination of cyclin B, Nek2A and Nek2A 333-445 are similarly sensitive to the SAC, when it would have been expected that only Nek2A would be a substrate of SAC-inhibited APC/C. In fact there appears little difference between rates of Nek2A ubiquitination between SAC-inhibited and uninhibited APC/C -and in both conditions the degree of Nek2A ubiquitination is very low despite the high amounts of unmodified Nek2A (Fig. 6A ).
The fact that Nek2A is sensitive to the SAC in in vitro assays is exactly our point and has also been shown by others. There is a very reproducible delay in Nek2A ubiquitinationwhen using APC/C from checkpoint arrested cells. Why Nek2A is a inefficientsubstrate in vitro is not clear to us but we merely use this assay to illustrate that Nek2A is sensitive to the presence of the MCC.
9. In the RNAi experiment Fig. 6B , depletion of Apc8 (and IP on Apc4) also leads to loss of Apc10 and Apc11. This indicates that depletion of Apc8 leads to almost complete disassembly of the APC/C (not just loss of Apc8, Apc6 and Apc3 as the authors mention). From this experiment it is not possible to conclude that Nek2A binds to Apc8.
Unfortunately the reviewer did not compare the APC8 depletion to that of APC2 and APC10, which clearly shows that APC10 and APC11 are not involved in binding Nek2A. As mentioned above we will include blots of additional subunits and test the effect of an APC8 point mutant.
10.In Fig. 6F . In the presence of MG132 why didn't the authors test Nek2A binding to the APC/C-MCC (IP on BubR1)?
Our response: This is exactly what we did in fig 6E so the reviewer misunderstood this experiment. We will try and make that more clear in the revised version.
11.What is the evidence that Cdc20 is required for Nek2A degradation at prometaphase -as mentioned in the Abstract and last line of the Introduction?
Our response: This has been shown by work from the Fry lab and we will make sure that this is more clear in the revised version.
12.Indicate prometaphase and metaphase on plots in Fig. 3 . Our response: We will do this.
13.Other points. The manuscript contains numerous typographical and grammatical errors and references are incomplete.
We have tried extensively to avoid this and also include all relevant references within the space constrictions there are. We will improve on this.
Theanaphase-promoting complex or cyclosome (APC/C) in collaboration with its mitotic activator Cdc20 mediates the ubiquitination of many mitotic regulators, resulting in their orderly destruction that drives mitotic progression. APC/C-Cdc20 is the target of the spindle checkpoint, which limits APC/C activity until all sister kinetochores achieve bi-orientation. Certain APC/C substrates such as Nek2A escape checkpoint inhibition and are degraded prior to the metaphase-anaphase transition.
The mechanism by which Nek2A escapes checkpoint inhibition is incompletely understood, but has been shown to require the binding of its C-terminal MR motif to APC/C. In the current study, Sedgwick et al. further investigated the mechanism by which Nek2A evaded the checkpoint. They began their study by identifying Kif18A as a novel APC/C-Cdc20 substrate and show that it too required the C-terminal LR motif for ubiquitination. Unlike Nek2A, Kif18A ubiquitination and degradation are regulated by the spindle checkpoint, however. This result promoted the authors to search for additional determinants in Nek2A that mediate its degradation when the checkpoint is on. These efforts led to the evidence that implicated a requirement for the leucine-zipper motif of Nek2A in this process. Overall, their results provide additional insights into how APC/C recognizes substrates and how the checkpoint regulates substrate recognition by APC/C. These findings are significant, and are in principle appropriate for publication in EMBO J. The authors need to address my following concerns prior to publication.
(1)The authors conclude the APC/C-binding activity of the leucine-zipper is dependent of its ability to mediate dimerization. This conclusion is not well supported by their data. If the LL-AA mutant of Nek2A only weakens APC/C binding slightly (as the authors argue), how does the coiled coil motif contribute to APC/C-dependent ubiquitination? It remains formally possible that both MR motifs in the wild-type Nek2A homodimer cooperatively engage APC/C. Mutations of the leucine-zipper disrupt the dimerization of Nek2A, and as a consequence, weaken the bipartite interaction between MR and APC/C. This is consistent with the fact that the isolated leucine-zipper domain of Nek2A does not bind to APC/C. Obviously tethering the MR motif to the dimeric Kif18A was not sufficient to confer prometaphase degradation, indicating that dimerization of MR motif per se is not sufficient. The authors should nonetheless test whether tethering Nek2A MR motif to a small leucine-zipper domain found in transcription factors would be sufficient to create an APC/C substrate that evades the spindle checkpoint.
Our response: I must point out that "The authors conclude the APC/C-binding activity of the leucine-zipper is dependent of its ability to mediate dimerization" is NOT our conclusion. Our analysis of Nek2A L313A/L320A mutant shows that the role of the leucine zipper in APC/C binding is not only due to a role in dimerization, although there is some contribution from dimerization. As shown by the Fry lab the Nek2A leucine zipper is quite an unusual leucine zipper and therefore I expect that it isuniquely suited for its binding to the APC/C. We will improve on the writing part to more clearly state this.
(2)The paper contains two novel discoveries: the identification of Kif18A as an APC/C-Cdc20 substrate and the identification of the leucine-zipper motif as an additional determinant for prometaphase degradation of Nek2A. The connection between these two discoveries is obvious, but not as strong as it can be. The authors should do a better job in their writing to integrate these two findings.
We will improve the writing to integrate and explain our observations. Thank you for your correspondence in response to my decision and the referee reports on your recent submission, EMBOJ-2012-. I have now had a chance to consider your points in detail, and I appreciate that many of your answers and clarifications do sound reasonable. I would therefore be willing to allow you an opportunity to respond directly to the reviewers in the form of a revised version of the manuscript, which you will be able to submit using the link provided below. I should however make clear that we will (as always) only be able to consider a single round of major revision, and that it will therefore be essential to thoroughly address all the specific points raised at this stage. Also, I notice that several of your answers have remained at this point tentative and depending on the outcome of planned revision experiments; so I hope you understand that I am currently not in a position to make any strong predictions on ultimate acceptance or rejection of the new version, which will depend on convincing the referees that their key concerns had been largely clarified.
Please do not hesitate to get back to me should you have any further questions in this regard.
Sincerely,
Editor
The EMBO Journal 1st Revision -authors' response 05 November 2012
Please find enclosed our manuscript entitled "Mechanisms controlling the temporal degradation of Nek2A and Kif18A by the APC/C-Cdc20 complex" which we are resubmitting to the EMBO Journal. We have dealt extensively with the concerns of the reviewers, listed point by point in the rebuttal and incorporated several new major observations in the revised manuscript as listed below:
-Through careful analysis of Nek2A leucine zipper mutants we find that the requirement for this domain is to dimerize Nek2A to allow stable APC/C binding and avoid SAC inhibition.
-We show that Kif18A can be targeted for degradation at NEBD if fused to Nek2A 370-445. Since Kif18A is a dimer this shows that dimerization of Nek2A 370-445 suffices to escape inhibition by the SAC.
-We have removed the previous Nek2A 265-445 stable cell line from the revised manuscript as we found it was cleaved to liberate free Venus, explaining why we did not detect degradation of this fusion protein. We analysed other truncations around this region and found that Nek2A 301-445 did not have this problem of spontaneous cleavage. We have used this construct instead and as expected Nek2A 301-445 is degraded at NEBD -We have extensively expanded on the requirements for TPR subunits in binding of Nek2A to the APC/C and find that similarly to the MCC, Nek2A binding is sensitive to the APC8 N338A mutation providing stronger evidence for our original proposal that APC8 was required for Nek2A binding.
Combined our results provide significant novel insight into the degradation of APC/C substrates containing IR like motifs and how Nek2A avoids SAC inhibition. Given the importance of the APC/C in regulating mitosis as well as other aspects of cell function this study will be of general interest to a wide audience.
This manuscript describes how Nek2A can be destroyed even when the spindle assembly checkpoint (SAC) is active. The APC/C was purified from nocodazolearrested and released HeLa cells and associated proteins determined by mass spectrometry. The authors identified Kif18A and Nek2A and intriguingly both proteins terminate in a similar dipeptide motif to Cdc20/Cdh1 (IR); LR in Kif18A and MR in Nek2A. Initial studies showed that Kif18A destruction during mitosis was dependent on the LR motif and Cdc20. However, Kif18A was degraded in anaphase, unlike Nek2A which starts to degrade in prometaphase. Thus, investigation into the mechanism of Nek2A degradation during prometaphase was carried out. The authors showed that the MR motif in Nek2A was not sufficient to target it for degradation during an active checkpoint but the region from 265-333 might be involved. From further investigation, the conclusion that the leucine zipper of Nek2A in combination with the MR motif is essential to provide its higher affinity binding to the APC/C in prometaphase was proposed. It is an interesting model, however, the data quality and interpretation raises some concerns. The manuscript will be improved if the following points are addressed.
We have carefully looked again at the time-lapse movies of the different Nek2A constructs but find no consistent trend that any specific construct delays anaphase onset. We have added an explanation of this in the text (page 9-10). Where possible we have shown cells with similar NEBDanaphase timing to make comparison between traces easier. As is normally observed in single cell studies there is variation in NEBDAnaphase timing but despite this variation all the different Nek2A constructs always initiate their degradation at either NEBD or Anaphase.
2. Figure 4A . Please explain why the Venus-Nek2A 265-445 construct produces such a GFP rich band. Is this fusion protein unstable in cells and cleaved? In contrast, Figure S3 suggests that it is stable. Is it possible that the authors measured degradation of GFP (Venus), rather than the fusion protein (VenusNek2A 265-445) in Figure S3 ? If the authors' hypothesis is correct, 265-445 could degrade reasonably well in prometaphase because it has both the LZ and MR motif.
We thank the reviewer for suggesting this possibility, which we have investigated. Indeed it appears that in the stable U2OS cell line expressing Venus Nek2A 265-445 the Venus tag is cleaved off the Nek2 sequence, but that this is not observed when we transiently express it (previous Figure  S3) . We have observed this cleavage of the Venus tag with Venus Nek2A 291-445 as well, suggesting fusions around that region are prone to spontaneous cleavage. Venus Nek2A 301-445 does not have this problem and so we have used this new Nek2A construct in the revised manuscript. Nek2A 301-445 is degraded at NEBD in line with the fact that it contains the LZ (new figure 4D) .
3. Figure 4B . The pull down assay using anti-APC4 antibody suggests that LZ mutations reduce the interaction between Nek2A and APC/C. However, the mutations could inhibit formation of the Nek2A dimer as suggested in Figure 4D . If so, the reduced recovery of Nek2A may be due to defects on its dimer formation, rather than direct interaction between Nek2A and the APC/C. I would rather suggest to re-do the experiment in a reciprocal way; pull down using antiNek2A antibody (FLAG) and measure the amount of APC/C co-purified.
We again thank the reviewer for suggesting this experiment, which we have performed (new figure 5F-G). Indeed when we IP Nek2A LZ mutants they are strongly impaired in binding to the APC/C and this correlates exactly with their reduction in dimerization as judged by their binding to myc-Nek2A. Based on this finding we reinvestigated the binding of Nek2A L313A/L320A to the APC/C in APC4 IPs and found that at low expression levels it is strongly impaired in binding (new figure 5D-E) but at the higher levels of expression used in the original submission there is only a minor reduction in binding. These new findings clearly support the idea that the LZ mediates stable Nek2A binding to the APC/C via dimerization and we have revised our manuscript according to these new results.
We have undertaken a more extensive analysis of the role of different APC/C subunits in binding to Nek2A (new figure 7 A-C) and also analyzed the interdependencies of the different APC/C subunits (new supplemental figure 5 ). The MCC and Nek2A are both sensitive to the removal of single TPR subunits, which under our conditions are due to strong dependencies between them. To directly test the role of APC8 in Nek2A binding we have analyzed a recently described APC8 mutant, APC8 N338A, that is defective in MCC binding. Similar to the MCC, Nek2A binding is also sensitive to this mutation suggestion that APC8 is important (new figure 7 D-E).
We are by no means proposing this is a general mechanism accounting for the timing of destruction of all substrates of the APC/C. We are merely stating that for Nek2A there is a clear correlation between stable binding to the APC/C and its ability to be degraded during an active checkpoint. Please also note that in the in vitro ubiquitination assay we use Cyclin B1 1-86, which is a very effective in vitro substrate that is widely used in the field, but might not reflect the Cyclin B1-Cdk1 complex. We merely use it as a control substrate.
6. The authors do not mention the KEN-box of Nek2A at all. I would like to know the contribution of the KEN-box in Nek2A degradation during prometaphase. In addition, the KEN-box might be more important than the MR motif in Nek2A degradation in anaphase. Have the authors investigated Venus Nek2AΔ;KEN, Nek2AΔ;KENΔ;MR or Nek2A Δ;333-445Δ;KEN in the live cell degradation assay?
We have now included the KEN box in our analysis but this is not required for degradation during an active checkpoint (new figure 4B) . We have also now included the analysis of a Kif18A-Nek2A 370-445 fusion, which is degraded during an active checkpoint (new figure 3C ). This shows that additional motifs in Nek2A 370-445 that are likely not the KEN box are required for degradation during prometaphase. We have included this in the discussion.
We have repeated that experiment and used vinculin as a loading control.
2. Figure 2B and C, the same control (tubulin or vinculin) should be used to compare the effect of Cdh1 or Cdc20 depletion. The panels should be arranged 4 in the same order in both experiments
We have repeated the experiment originally shown in figure 2B and used vinculin as a loading control. Both figures have the panels in the same order now.
In our assays were we deplete Cdc20 there appears to be a slight delay in exit from mitosis when RO3306 is added. This of course affects the degradation profile of APC/C substrates such that they are degraded later. We do not know the cause of this delay but speculate it could be that mitotic exit is not as efficient when Cdc20 has been depleted despite the direct inhibition of Cdk1. This has also been observed by the Taylor lab (Gurden MDJ et al 2010 Figure 7 ).
Sedgwick et al identify a novel APC/C substrate Kif18A. Its degradation is dependent on its C-terminal LR motif (similar to the IR tail of coactivators and Apc10 and MR tail of Nek2A). However Kif18A is degraded at anaphase and the MR of Nek2A is not sufficient to target Kif18A for degradation during an active checkpoint. The authors investigate timing of Nek2A degradation and show that a Leu-zipper (residues 310-34) is required for high affinity binding and for Nek2A degradation in prometaphase.
In figure 1A the cells have been arrested overnight with nocodazole and since Nek2A is degraded during an active checkpoint it is simply not present in cells under these conditions and we therefore do not detect it. In all the experiments where we look at endogenous Nek2A-APC/C interaction we add MG132 to prevent Nek2A degradation and removal from cells.
2. The presence of D box and KEN box degrons in Kif18A was not discussed. Do these determine timing of Kif18A degradation? What determines the dependence of Kif18A degradation on satisfying the SAC? The authors discuss that the LR motif is recognised at anaphase when the APC/C becomes fully active. Can the authors suggest a mechanistic explanation? Can the authors explain why Kif18A degradation is dependent on both Cdc20 and the LR motif?
We have included the analysis of additional Kif18A constructs, which suggests that motifs in the region from 453-652 are also required for degradation at anaphase (new Fig S1A) . We believe that the LR motif acts to bind Kif18A to the APC/C but that for degradation there must be motifs in 453-652 that is recognized by Cdc20 to target Kif18A for degradation and we have included this in the discussion of the revised manuscript.
We have included an explanation and a schematic of Nek2A in the revised manuscript.
We agree that it is not surprising that constructs without the MR tail are degraded at anaphase since these constructs contains destruction motifs. What is surprising is that the shorter fragments that do contain an MR motif are also anaphase substrates.
5. Page 10 (Fig. 4) 6. The authors propose that Nek2A binds to apo-APC/C and its degradation is controlled by Cdc20. What distinguishes Nek2A from binding to APC/C-Cdc20 at prometaphase from securin and cyclin B which isn't degraded at prometaphase?
What appears to be unique to Nek2A is that it does not require a coactivator for binding to the APC/C since it uses its MR motif to directly bind the APC/C as shown by the Fry lab (Hayes 2006). On the other hand securin and Cyclin B1 both depend on Cdc20 and APC10 for binding to the APC/C and this is mentioned in the introduction.
7. Fig.5 shows that the leu zipper is required to confer Nek2A degradation during an active SAC. Although the authors interpret their data to indicate the Leu zipper is required to mediate high affinity Nek2A-APC/C binding, they don't discuss whether this is due to direct binding to the APC/C (in the context of Nek2A) or the possibility that the Leu zipper plays a structural role to position the D box, KEN box and MR motifs in the optimal orientation for APC/C binding.
Our more extensive characterization of Nek2A L313A/L320A in the revised manuscript clearly suggests that the leucine zipper is required for dimerization rather than making a direct contact to the APC/C. We discuss this in the revised manuscript.
8. The authors should explain why when describing the data in Fig. 6A (page 12) they indicate that the ubiquitination of cyclin B, Nek2A and Nek2A 333-445 are similarly sensitive to the SAC, when it would have been expected that only Nek2A would be a substrate of SAC-inhibited APC/C. In fact there appears little difference between rates of Nek2A ubiquitination between SAC-inhibited and uninhibited APC/C -and in both conditions the degree of Nek2A ubiquitination is very low despite the high amounts of unmodified Nek2A (Fig. 6A ). 9. In the RNAi experiment Fig. 6B , depletion of Apc8 (and IP on Apc4) also leads to loss of Apc10 and Apc11. This indicates that depletion of Apc8 leads to almost complete disassembly of the APC/C (not just loss of Apc8, Apc6 and Apc3 as the authors mention). From this experiment it is not possible to conclude that Nek2A binds to Apc8.
We have included the analysis of the recently described APC8 mutant, APC8 N338A, which reveals that Nek2A binding to the APC/C is sensitive to this mutation. As this APC8 mutant maintains the APC/C structure it reveals that Nek2A at least in part depends on APC8.
10. In Fig. 6F . In the presence of MG132 why didn't the authors test Nek2A binding to the APC/C-MCC (IP on BubR1)?
This is exactly what we did and there is no binding of Nek2A in APC/C-MCC complexes (BubR1 IP).
11. What is the evidence that Cdc20 is required for Nek2A degradation at prometaphase -as mentioned in the Abstract and last line of the Introduction? 12. Indicate prometaphase and metaphase on plots in Fig. 3 .
We did not use a fluorescent chromosome marker in our live cell degradation experiments and without this it is very difficult based on DIC alone to exactly determine when all chromosomes have congressed and true metaphase occurs. A similar problem in accurately scoring metaphase exists when the plane of the metaphase plate is parallel to the focal plane. For these reasons we have not indicated metaphase in the live cell experiments. We have indicated NEBD and anaphase, both of which we feel can be confidently scored from DIC.
13. Other points. The manuscript contains numerous typographical and grammatical errors and references are incomplete.
We have tried our utmost to avoid errors and missing references in the revised manuscript. Thank you for submitting your revised manuscript for our consideration. Two of the original referees have now reviewed it once more (see comments below), and I am pleased to inform you that both of them consider the manuscript significantly improved and now suitable for publication in The EMBO Journal. We shall therefore be happy to accept the study, following additional modification of a number of remaining editorial issues, as follows:
-Referee 2 has some minor comments regarding introduction and discussion that I would kindly ask you to take into account in a final round of text modification.
-I noticed that not all contributing authors are listed in the Author Contribution statement at the end of the paper -please amend this section and make sure to specify every author's contribution.
-Please combine all supplementary information (text & figures) into a single PDF of sufficiently high image quality and sufficiently small file size (i.e. less than 10 Mb), to facilitate download by our readers.
-Regarding statistical analysis, I noticed that several diagrams (e.g. Figures 7B , &C, S4) contain mean values and error bar calculations for only two replicates. Since standard deviations for N=2 are not statistically meaningful, we would require either an increase in the number of experimental replicates (to N{greater than or equal to}3) to allow for proper statistical analysis (e.g. SEM calculation), or a re-plotting of these data to show individual data points in vertical arrangement instead of a column plot. Please refer also our Guide to Authors for further reference and guidance on these issues.
I am therefore returning the manuscript to you for one final round of minor revision, hoping you will be able to upload and re-submit the final corrected version as soon as possible. Should you have any questions in this regard, please do not hesitate to contact me directly.
With best regards, Editor The EMBO Journal
------------------------------------------------
Referee #1 (Remarks to the Author):
The manuscript has been improved greatly by performing several new experiments and clarification.
